RAC 2.92% $1.94 race oncology ltd

Ann: Updated Strategy and Investor Presentation, page-375

  1. 90 Posts.
    lightbulb Created with Sketch. 26
    If I remember correctly, the recruitment in the AML EMD trial was a problem becasue it took into account some information from KOLs that turned out to be inaccurate (that EMD was or could be screened in AML patients).

    The current strategy also relies on input from KOLs.

    Was anything done differently when collecting or analysing KOL input this time to reduce the likelihood of this happening again?
    Last edited by ReNova: 04/12/23
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.